Clinically studied. Recommended by 2,000+ verified clinicians. 15M+ NOVOS servings enjoyed worldwide. 81% of NOVOS customers feel a difference within 2 weeks
University researchers tested the complete NOVOS Core formula in a six-month, placebo-controlled human study.
MANUSCRIPT UNDER PEER REVIEW
Putting the results in context
The STAMINA trial measured endothelial function, arterial flexibility, and systolic blood pressure against placebo.
*Cross-study comparison, not head-to-head. Comparator values are published averages from separate studies with different populations and protocols.
Placebo-adjusted differences at six months. † For blood pressures already within the normal range.
The complete formula, tested in people.
Why these markers
Arteries stiffen and the vessel lining becomes less responsive as we get older. These changes are gradual and usually produce no symptoms, so most people never think about them until much later in life.
That is why STAMINA measured vascular function directly — endothelial function, arterial flexibility and blood pressure — rather than relying on how people felt. These are objective, measurable markers of how the cardiovascular system is functioning today.
NOVOS Core was formulated to target the twelve hallmarks of aging, not cardiovascular function specifically. These vascular results suggest that supporting the biology of aging may have favorable downstream effects on organ health. We began with heart health because cardiovascular disease is the leading cause of death worldwide, and because a healthy cardiovascular system delivers nutrients to every organ and cell. Future studies will need to confirm effects in other organs and systems.
Educational context only. NOVOS Core is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease, including cardiovascular disease. These statements have not been evaluated by the Food and Drug Administration.
Why this research matters
Most supplement evidence stops at individual ingredients. Biological research shows that combining ingredients can counteract their effects, and sometimes even lead to negative effects. Learn more.
NOVOS went further: the complete Core formula people use every day was compared with an identical-looking and tasting placebo.
The question behind every study is personal: “Could this work for me?” In this analysis, every NOVOS Core participant showed a favorable change, and nearly all did so across multiple cardiovascular measures.
100%
showed a favorable change in at least 1 of 3 cardiovascular measures*
95.7%
showed favorable changes in 2 to 3 cardiovascular measures*
*Exploratory post hoc analysis of the NOVOS Core STAMINA participants with complete 6-month data across all 3 measures. Favorable direction: FMD ↑, PWV ↓, SBP ↓.
61 adults randomized
33 assigned to NOVOS Core
28 assigned to placebo
Preprint. Manuscript under peer review.
Professor Christian Heiss
Professor of Cardiovascular Medicine, University of Surrey
Professor Christian Heiss is Professor of Cardiovascular Medicine at the University of Surrey, an NHS consultant interventional angiologist, and an internationally recognized expert in vascular medicine and human cardiovascular interventions.
University of Surrey biography (opens in a new tab)Funding and research control
NOVOS supplied the intervention and placebo and provided an unrestricted research grant. NOVOS had no role in data collection, primary statistical analysis, or interpretation. The academic investigators retained control of the study data and the decision to publish.
A closer look
Select a measure to see exactly how the comparison was calculated and what it can, and cannot, tell us.
Flow-mediated dilation (FMD)
FMD measures how effectively an artery widens in response to increased blood flow. It directly assesses the responsiveness of the vessel lining, called the endothelium.
Interpretation
The prespecified primary endpoint showed a large and statistically strong improvement versus placebo.
What it does not prove
FMD is a validated physiological marker, but this study did not measure heart attacks, strokes, or lifespan.
Carotid-femoral pulse wave velocity (PWV)
PWV measures how quickly a pressure wave moves through the arteries. Lower values generally indicate more flexible large arteries.
Interpretation
The result was consistent with a meaningful improvement in arterial flexibility.
What it does not prove
Population research finds PWV tends to worsen by roughly 1 m/s per decade, which gives a sense of scale. The study did not test whether Core reversed any amount of arterial aging, and no such equivalence should be read into the result.
Seated systolic blood pressure
Systolic blood pressure is the peak pressure in the arteries as the heart contracts. Baseline means were approximately 128 mmHg in the Core group and 125 mmHg in the placebo group — not in the hypertensive range.
Interpretation
The placebo-adjusted difference was substantial for a generally healthy population whose average baseline blood pressure was not in the hypertensive range.
What it does not prove
This supports healthy systolic blood pressure in a non-hypertensive population. It does not show that Core treats hypertension.
Six-month results are the headline of this trial. The acute measurement is secondary: FMD was also recorded one hour after the first dose.
Measured one hour after the first dose, consistent with the manuscript.
Values shown are the six-month analyses reported in the preprint, which remains under peer review. Flow-mediated dilation (FMD) is reported in percentage points.
Putting the magnitude in context
NOVOS reviewed randomized trials of commonly marketed heart-health supplement ingredients, retaining both positive and null findings. In strict, like-for-like fasted comparisons, Core’s effects ranked at the top.
Across the 55 strict, like-for-like fasted comparisons NOVOS reviewed, no other supplement matched Core’s effect size on all three vascular markers at once.
34of 36
Core’s effect was greater than 94% of strict fasted comparisons.
8of 8
Core’s effect was larger than 100% of strict fasted comparisons.
7of 11
Core’s effect was larger than the majority of strict fasted comparisons.
Cross-study comparison, not head-to-head. Values come from separate studies with different populations and protocols.
The peak pressure inside the arteries as the heart contracts.
A 2 mmHg improvement in systolic blood pressure is considered medically relevant. NOVOS Core's placebo-adjusted difference was large and meaningful for a generally healthy, non-hypertensive population.
NOVOS CORE VS. OTHER SUPPLEMENTS
NOVOS CORE VS. LIFESTYLE INTERVENTIONS
Beneficial effects on maintenance of healthy blood pressure already within the normal range
| Supplement | Healthy Blood Pressure | Arterial Flexibility | Endothelial Function |
|---|---|---|---|
| NOVOS Core | 3 of 3 | 3 of 3 | 3 of 3 |
| Omega-3 / Fish oil | 2 of 3 | 2 of 3 | 2 of 3 |
| Beetroot / Nitrate | 2 of 3 | 1 of 3 | 2 of 3 |
| Magnesium | 1 of 3 | ✕ | ✕ |
| Folate | 1 of 3 | – | 2 of 3 |
| L-Arginine | 1 of 3 | – | 2 of 3 |
| Garlic | 2 of 3 | ✕ | 1 of 3 |
| L-Carnitine | 1 of 3 | – | – |
| Spirulina | 1 of 3 | – | ✕ |
Not a head-to-head comparison. These values come from separate studies involving different populations and protocols.
NOVOS Core is not a replacement for exercise, diet, sleep, and other healthy behaviors, which remain foundational. Comparisons shown to contextualize significance of effect size in STAMINA trial.
The complete NOVOS Core formula: the same 15 grams studied for six months against placebo.
Individual results vary. NOVOS Core is not intended to diagnose, treat, cure, or prevent any disease.
Complete record
Evidence hierarchy
Human randomized researchThe gold standard: The best evidence on whether the finished formula changes measured human physiology versus placebo.
Human pilot researchUseful for detecting promising before-and-after signals, and promising paths for placebo-controlled human clinical research.
Animal researchCan measure lifespan and healthspan directly under controlled conditions, to see if hypotheses translate into mammalian outcomes.
Cell researchCan reveal mechanisms under tightly controlled laboratory conditions, to help understand how a formulation biologically works.
Eight people improved beyond the test's reported error margin; three showed no statistically meaningful change in either direction. Nobody's pace of aging increased in the study.
Interpretation
The consistency of the signal supports further randomized research into Core + Boost and biological pace of aging.
DunedinPACE is an epigenetic test. It reads chemical marks on DNA and returns an estimate of how quickly a person's biology appears to be changing, expressed as a pace: a value near 1.0 means roughly one year of biological change per calendar year. It is an estimate derived from a reference population, not a direct measurement of lifespan or health outcomes.
Core versus control: approximately +18% median survival, log-rank p = 0.045. The senolytic arm includes a Rx drug and R&D drug(navitoclax plus BAM15) served as a positive control; its median was numerically similar to Core.
ESSENTIAL CAVEATS
Supporting evidence
WHAT TO KEEP IN MIND Very small pilot. The result is hypothesis-generating and requires confirmation in a larger controlled study.
WHAT TO KEEP IN MIND Peer reviewed and performed in laboratory skin cells (in vitro).
WHAT TO KEEP IN MIND This shows an effect under controlled cell-culture conditions (in vitro).
WHAT TO KEEP IN MIND This is mechanistic in vitro support.
This literature informed the selection of Core's ingredients, doses, and biological targets. Ingredient research explains the scientific rationale for the formula. It does not replace finished-product evidence.
950+ refers to ingredient-level studies reviewed during formulation — not 950 trials of NOVOS Core.
Select a hallmark
Core's ingredients were selected against the hallmarks of aging. Choose one to see what it describes, then open the full evidence library for the underlying ingredient studies, study types and outcomes.
For the careful reader
Yes. The human trial used the complete 15-gram multi-component NOVOS Core formulation, rather than testing one isolated ingredient.
Sixty-one received their assigned intervention. The primary complete-case analysis included the 43 participants with both baseline and six-month FMD measurements. Attrition is an important limitation and should be considered when interpreting the results.
The manuscript is a preprint and remains under peer review. That status is stated everywhere the trial is summarized on this page.
NOVOS supplied the study products and provided an unrestricted research grant. The manuscript states that the academic investigators controlled data collection, primary analysis, interpretation, and the decision to publish.
No. FMD, PWV, systolic blood pressure, and SCORE2/SCORE2-OP showed favorable results. Several other measurements, including lipids and diastolic blood pressure, did not significantly differ between groups.
No. It showed favorable effects on vascular and hemodynamic markers. It was not designed to measure cardiovascular events.
No. Lifespan was measured in mice, not humans.
No. It tested the full formula and cannot isolate the contribution of each ingredient.
No. Group averages do not mean that every participant experienced the same response. Individual results will vary.
THE FORMULA STUDIED IN THE STAMINA TRIAL
Twelve ingredients designed around the interconnected biology of aging. One packet daily. Tested as a complete formulation across randomized, double-blind, placebo-controlled human research; animal lifespan; and in vitro research.
Individual results vary. NOVOS Core is not intended to diagnose, treat, cure, or prevent any disease.
References
Every quantitative claim on this page comes from one of the sources below. The STAMINA manuscript is a preprint under peer review. Independent literature is listed separately from NOVOS-funded research.
